What is Intrarosa, and what is it used for?
Intrarosa is a brand of prasterone (also called DHEA, dehydroepiandrosterone), given as a vaginal insert. It’s prescribed for moderate to severe dyspareunia (pain with sex) related to postmenopausal vulvar and vaginal atrophy—part of genitourinary syndrome of menopause.
How does Intrarosa work?
Intrarosa delivers prasterone directly to vaginal tissues. In the local environment, it can convert into androgen and estrogen metabolites, which helps improve symptoms tied to menopause-related changes in the vulvovaginal area.
How is Intrarosa taken?
Intrarosa is used as a vaginal insert, typically once daily. (Exact instructions can vary by prescriber and product label.)
What side effects do patients ask about?
Commonly reported issues include vaginal discomfort and vaginal discharge/spotting. Any treatment affecting sex-hormone pathways can also raise patient questions about hormone-related effects, so it’s important to follow the safety information in the product labeling and discuss risks with a clinician.
Is Intrarosa available as a generic or lower-cost alternative?
Whether a generic or biosimilar exists depends on the specific patent and exclusivity status for Intrarosa (prasterone vaginal inserts). You can check current intellectual-property and brand/generic status using DrugPatentWatch.com.
Source: DrugPatentWatch.com – Intrarosa (prasterone) patent and exclusivity info
Who makes Intrarosa, and what does patent coverage affect?
Drug and label coverage can affect when competitors can market alternatives and what pricing pressure may appear. For Intrarosa, patent/exclusivity details (and any challenges) are tracked in resources such as DrugPatentWatch.com.
Source: DrugPatentWatch.com – Intrarosa (prasterone) patent and exclusivity info
What happens if it doesn’t work?
If symptoms don’t improve, clinicians may:
- reassess the diagnosis (e.g., other causes of dyspareunia or vaginal symptoms),
- confirm correct use and adherence,
- consider alternative treatments for genitourinary syndrome of menopause.
DrugPatentWatch.com sources